Related Experiment Video

Updated: Nov 5, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.1K

Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance

Ka Shing Cheung1,2, Lung Yi Mak1, Lok Ka Lam1

  • 1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

Hepatology International
|May 14, 2021
PubMed

Insights

Long-term outcomes for chronic hepatitis B (CHB) patients after HBsAg seroclearance are generally favorable. However, statin use was associated with significantly reduced risks of cirrhosis, hepatocellular carcinoma (HCC), and all-cause mortality.

Area of Science:

  • Hepatology
  • Clinical Medicine
  • Virology

Background:

  • Chronic hepatitis B (CHB) is a significant global health concern.
  • Hepatitis B surface antigen (HBsAg) seroclearance marks a milestone in CHB management.
  • Long-term outcomes post-HBsAg seroclearance require detailed characterization.

Purpose of the Study:

  • To elucidate long-term clinical outcomes in CHB patients following HBsAg seroclearance.
  • To identify factors influencing disease progression and adverse events.
  • To investigate the potential benefits of statin therapy in this patient cohort.

Main Methods:

  • Retrospective cohort study of CHB patients with HBsAg seroclearance (1986-2017).
  • Primary outcomes: cirrhosis and hepatocellular carcinoma (HCC). Secondary outcomes: hepatic decompensation, liver-related death/transplantation, and all-cause mortality.
  • Multivariable Cox regression and propensity score matching (PSM) were employed to analyze outcomes, including the effect of statin use.

Main Results:

  • Statins significantly reduced the risk of cirrhosis/HCC (aHR: 0.44) and all-cause mortality (aHR: 0.21).
  • Statin users experienced no hepatic decompensation or liver-related death/transplantation.
  • Factors associated with increased cirrhosis/HCC risk included older age, diabetes, elevated creatinine, GGT, and AFP levels.

Conclusions:

  • CHB patients achieving HBsAg seroclearance exhibit favorable long-term survival.
  • Despite favorable outcomes, liver-related adverse events can still occur.
  • Further research into the beneficial effects of statins in CHB patients post-seroclearance is warranted.
Abstract

Keywords:
Anti-HBsCHBHBVS-lossSeroclearanceStatins

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.7K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
46
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
55
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
357
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
55
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
299